MUNSTER, Lukas, Michaela FOJTŮ, Zdenka CAPAKOVA, Tomáš VACULOVIČ, Michaela TVRDOŇOVÁ, Ivo KURITKA, Michal MASAŘÍK and Jan VICHA. Selectively Oxidized Cellulose with Adjustable Molecular Weight for Controlled Release of Platinum Anticancer Drugs. Biomacromolecules. Washington: American Chemical Society, 2019, vol. 20, No 4, p. 1623-1634. ISSN 1525-7797. Available from: https://dx.doi.org/10.1021/acs.biomac.8b01807.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Selectively Oxidized Cellulose with Adjustable Molecular Weight for Controlled Release of Platinum Anticancer Drugs
Authors MUNSTER, Lukas (203 Czech Republic), Michaela FOJTŮ (203 Czech Republic, belonging to the institution), Zdenka CAPAKOVA (203 Czech Republic), Tomáš VACULOVIČ (203 Czech Republic, belonging to the institution), Michaela TVRDOŇOVÁ (203 Czech Republic, belonging to the institution), Ivo KURITKA (203 Czech Republic), Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution) and Jan VICHA (203 Czech Republic).
Edition Biomacromolecules, Washington, American Chemical Society, 2019, 1525-7797.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10608 Biochemistry and molecular biology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.092
RIV identification code RIV/00216224:14110/19:00107804
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1021/acs.biomac.8b01807
UT WoS 000464248300015
Keywords in English NMR CHEMICAL-SHIFTS; DENSITY-FUNCTIONAL THEORY; RELATIVISTIC DOUBLE-ZETA; HYALURONIC-ACID; DIALDEHYDE CELLULOSE; TRIPLE-ZETA; BASIS-SETS; PT-195 NMR; CISPLATIN; PERIODATE
Tags 14110515, 14110518, CF NMR, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 31/3/2020 22:07.
Abstract
The synthesis of selectively oxidized cellulose, 2,3-dicarboxycellulose (DCC), is optimized for preparation of highly oxidized material for biological applications, which includes control over the molecular weight of the product during its synthesis. Conjugates of DCC and cisplatin simultaneously offer a very high drug binding efficiency (>90%) and drug loading capacity (up to 50 wt %), while retaining good aqueous solubility. The adjustable molecular weight of the DCC together with variances in drug feeding ratio allows to optimize cisplatin release profiles from delayed (<2% of cisplatin released during 6 h) to classical burst release with more than 60% of cisplatin released after 24 h. The release rates are also pH-dependent (up to 2 times faster release at pH 5.5 than at pH 7.4), which allows to exploit the acidic nature of tumor microenvironment. Extensive in vitro studies were performed on eight different cell lines for two cisplatin-DCC conjugates with different release profiles. In comparison with free cisplatin, both cisplatin-DCC conjugates demonstrated considerably lower cytotoxicity toward healthy cells. Conjugates with burst release profiles were found more effective against prostate cell lines, while DCC conjugates with slower release were more cytotoxic against ovarian and lung carcinoma cell lines. In vivo studies indicated a significantly longer survival rate, a reduction in tumor volume, and a higher accumulation of platinum in tumors of mice treated with the cisplatin-DCC conjugate in comparison to those treated by free cisplatin.
Links
GA16-05961S, research and development projectName: Pokročilé nosiče platinových léčiv
Investor: Czech Science Foundation
LM2015043, research and development projectName: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)
Investor: Ministry of Education, Youth and Sports of the CR
LM2015085, research and development projectName: CERIT Scientific Cloud (Acronym: CERIT-SC)
Investor: Ministry of Education, Youth and Sports of the CR, CERIT Scientific Cloud
MUNI/A/1255/2018, interní kód MUName: Kardiovaskulární systém a jeho regulace a dysregulace pod vlivem farmak (Acronym: KAREDYSFAR)
Investor: Masaryk University, Category A
MUNI/A/1553/2018, interní kód MUName: Genetické, environmentální a tkáňové charakteristiky vybraných patologických stavů a nemocí (Acronym: genetika; stres; biomateriály; tkáňové kultury)
Investor: Masaryk University, Category A
PrintDisplayed: 13/7/2024 17:30